Abeona Buys Phase 3-Ready ABO-801 for $20M Stock, Raises $30M PIPE at $3.75
ABEO is trading near its 52-week low of $3.91 (6.9% above the low).
Summary
Abeona acquired EoE candidate ABO-801 from Ellodi for $20 million in stock plus up to $60 million in milestones and tiered royalties, and raised $30 million in a private placement at $3.75 per share. The asset's prior Phase 3 trials missed their symptom endpoints, so the planned 2027 study uses a redesigned endpoint.
Key Events · M&A and Partnerships · ABEO
-
Acquires ABO-801 With Stock, No Cash
Abeona bought APT-1011 (now ABO-801), a Phase 3-ready oral fluticasone tablet for eosinophilic esophagitis, from Ellodi for $20 million in stock — 4,494,383 shares priced off the 20-trading-day VWAP — with no upfront cash.
-
$30M PIPE Priced at $3.75
The private placement sells 6,400,000 shares at $3.75 and pre-funded warrants for 1,600,043 shares at $3.7499 per warrant, about $30 million gross before fees, with Morgan Stanley as sole placement agent. Closing is expected November 10, 2026.
-
Milestones and Royalties to Ellodi
Ellodi can receive $30 million on FDA approval of ABO-801, up to $30 million on sales milestones, and tiered royalties from low to mid teen percentages on net sales.
-
Prior Phase 3 Missed Symptom Endpoints
Both completed Phase 3 studies showed statistically significant histologic and endoscopic improvements but missed their prespecified patient-reported symptom co-primary endpoints; Abeona plans a new Phase 3 starting Q2 2027 with topline by end-2028 using a DSQ-based symptom endpoint.
Analysis · ABEO · Life Sciences
Abeona is adding a second late-stage asset without spending cash: Ellodi gets $20 million of stock (4,494,383 shares) up front, with $30 million due on FDA approval and up to $30 million more on sales milestones plus low-to-mid-teen royalties. The $30 million private placement at $3.75 per share funds the pipeline and the ZEVASKYN launch. The catch is that ABO-801's two completed Phase 3 studies both missed their symptom co-primary endpoints, so the planned Phase 3 (starting Q2 2027, topline by end-2028) rests on a redesigned symptom endpoint the company argues would have worked. Existing holders absorb roughly 8 million new shares between the deal stock and the PIPE, and the Ellodi shares unlock in thirds over 18 months.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABEO was trading at $4.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238.5M. The 52-week trading range was $3.91 to $7.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.